Huntington’s Disease

About Huntington's Disease

Huntington’s Disease is a genetic neurodegenerative disorder that affects the patient’s normal movement, cognition and behaviour. There are currently no effective marketed treatments for HD.

IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development.

Neuroimaging requirements change throughout the course of a clinical study. IXICO offers the combination of expertise in HD through scaling up and validation; providing reproducible, regulatory compliant, analytical results through all phases of your study. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.

IXICO is committed to advancing HD science by working alongside the Huntington’s Disease Regulatory Science Consortium (HD-RSC) to review current evidence, identifiy evidence gaps and plann targeted research with potential to increase the efficiency, safety, and speed of HD drug development.

Huntington’s is a terrible disease with a huge unmet need, and patients and their families desperately want treatments that work.

Track record

  • IXICO played a pivotal role in standardising the acquisition of MRI data and characterising imaging biomarkers for HD during the TRACK-HD and Track-On HD studies.
  • We have provided advanced imaging analytics for 11 HD trials, demonstrating our market-leading position within the HD community.

Science consultancy

  • In house science provides optimum solutions for delivery of advanced imaging and wearables data science.
  • Protocol consultation at early stage to support Regulatory pathway.


  • Collaboration with International Consortia, academic Institutions and global networks of Research Sites enables efficient and effective delivery of imaging and other data science.

The patient

  • Patient centricity: gaining insights into people affected by Huntington’s disease coupled with training and technology improves recruitment, retention and support to trial participants.